Home Journals Articles Updates About
CN
image
收藏切换
Research progress on dual PDE3/4 inhibitors for the treatment of respiratory diseases
收藏切换
PDF
Min DONG, Xiang ZHANG*
Acta Pharmaceutica Sinica | 2021, 56(1) : 70 - 79
Less
收藏切换
Acta Pharmaceutica Sinica | 2021, 56(1): 70-79
• Reviews •
Research progress on dual PDE3/4 inhibitors for the treatment of respiratory diseases
Full
Min DONG, Xiang ZHANG*
Affiliations
  • Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Published: 2021-01-12 doi: 10.16438/j.0513-4870.2020-0928
Outline
收藏切换

Chronic obstructive pulmonary disease and asthma are complex inflammatory diseases with airway obstruction as the main characteristics, and have become common respiratory diseases that seriously affect human health. Compared with the clinical use of PDE3 or PDE4 inhibitors alone, dual PDE3/4 inhibitors have synergistic anti-inflammatory and bronchodilator effects, and have attracted widespread attention in recent years. This article reviews the representative research results of dual PDE3/4 inhibitors currently in the preclinical and clinical research stages, summarizing their latest progress and their potential for the treatment of chronic obstructive pulmonary disease and asthma.

phosphodiesterase  /  dual target  /  phosphodiesterase 3/4 inhibitor  /  chronic obstructive pulmonary disease  /  asthma  /  synergistic effect
Min DONG, Xiang ZHANG. Research progress on dual PDE3/4 inhibitors for the treatment of respiratory diseases[J]. Acta Pharmaceutica Sinica, 2021 , 56 (1) : 70 -79 . DOI: 10.16438/j.0513-4870.2020-0928
Appendix
Less
Year 2021 volume 56 Issue 1
PDF
201
92
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2020-0928
  • Receive Date：2020-06-09
  • Online Date：2025-12-18
  • Published：2021-01-12
Article Data
Affiliations
History
  • Received：2020-06-09
  • Revised：2020-07-05
Funding
Affiliations
    Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2020-0928
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House